Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talquetamab combinations versus daratumumab + pomalidomide + dexamethasone in relapsed or refractory multiple myeloma
ISRCTN12220131Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of talquetamab, daratumumab, pomalidomide and dexamethasone in multiple myeloma (MM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival. Started Oct 2022; status: active, not recruiting.
02
Drugs
talquetamabdaratumumabpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ISRCTN12220131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12220131.